Lonza signs agreement to manufacture AstraZeneca’s COVID-19 treatment October 30, 2020 BASEL: Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment…
Lonza appoints Pierre-Alain Ruffieux as new Chief Executive Officer June 5, 2020 BASEL, SWITZERLAND: The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020. Prior to that…
Moderna and Lonza announce strategic collaboration to manufacture vaccine against Novel Coronavirus May 1, 2020 BASEL, SWITZERLAND: Moderna Inc., a clinical stage biotechnology company, and Lonza Ltd. have announced a 10-year strategic collaboration agreement to enable larger scale manufacture…
Lonza expands Bioconjugation facility and announces approval of third commercial ADC July 24, 2019 BASEL, SWITZERLAND: Lonza has announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a…